title: Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.
abstract: The aim of this study was to investigate the changes in health-related profiles including quality-of-life (HRQoL) in the chronic myeloid leukemia (CML) patients who discontinued imatinib (IM). An HRQoL survey composed of 43 parameters about IM-related adverse events (AEs), physical health-related and mental health-related was provided at baseline and 6 months post-discontinuation. A total of 55 patients with a sustained UMRD over 6 months were analyzed. Although the majority of IM-related AEs were significantly improved, unexpectedly pruritus and musculoskeletal pain worsen or newly develop in 29.1% and 21.8% of patients, respectively. The improvements in physical and mental health condition were variable in individual patients. In addition, rapid restorations of the hematological and biochemical parameters were observed. The results showed the changes of HRQoL and laboratory tests in treatment-off patients and the necessity of continuing physical and mental support for some patients in tyrosine kinase inhibitor (TKI)-off studies.
authors.affiliation: a Department of Hematology-Oncology , Ajou University School of Medicine , Suwon , Korea.
authors.forename: Joon Seong
authors.initials: JS
authors.lastname: Park
authors.affiliation: b Department of Hematology , Seoul St Mary's Hospital, The Catholic University of Korea , Seoul , Korea.
authors.forename: Sung-Eun
authors.initials: SE
authors.lastname: Lee
authors.affiliation: a Department of Hematology-Oncology , Ajou University School of Medicine , Suwon , Korea.
authors.forename: Seong Hyun
authors.initials: SH
authors.lastname: Jeong
authors.affiliation: b Department of Hematology , Seoul St Mary's Hospital, The Catholic University of Korea , Seoul , Korea.
authors.forename: Eun-Jung
authors.initials: EJ
authors.lastname: Jang
authors.affiliation: b Department of Hematology , Seoul St Mary's Hospital, The Catholic University of Korea , Seoul , Korea.
authors.forename: Mi-Yeon
authors.initials: MY
authors.lastname: Choi
authors.affiliation: c Department of Hematology-Oncology , Chonnam National University Hwasun, Hospital , Hwasun , Korea.
authors.forename: Hyeoung-Joon
authors.initials: HJ
authors.lastname: Kim
authors.affiliation: c Department of Hematology-Oncology , Chonnam National University Hwasun, Hospital , Hwasun , Korea.
authors.forename: Yeo-Kyeoung
authors.initials: YK
authors.lastname: Kim
authors.affiliation: d Department of Internal Medicine , Dong-A University College of Medicine , Busan , Korea.
authors.forename: Sung-Hyun
authors.initials: SH
authors.lastname: Kim
authors.affiliation: e Department of Internal Medicine , Hallym University College of Medicine , Anyang , Korea.
authors.forename: Dae Young
authors.initials: DY
authors.lastname: Zang
authors.affiliation: f Division of Hematology-Oncology, Department of Internal Medicine , Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University , Seoul , Korea.
authors.forename: Sukjoong
authors.initials: S
authors.lastname: Oh
authors.affiliation: f Division of Hematology-Oncology, Department of Internal Medicine , Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University , Seoul , Korea.
authors.forename: Dong Hoe
authors.initials: DH
authors.lastname: Koo
authors.affiliation: g Division of Hematology and Cellular Therapy, Ulsan University Hospital, University of Ulsan College of Medicine , Ulsan , Korea.
authors.forename: Hawk
authors.initials: H
authors.lastname: Kim
authors.affiliation: h Division of Hematology-Oncology, School of Medicine, Keimyung University , Daegu , Korea.
authors.forename: Young Rok
authors.initials: YR
authors.lastname: Do
authors.affiliation: i Division of Hematology-Oncology, Chonbuk National University Medical School , Jeonju , Korea.
authors.forename: Jae-Yong
authors.initials: JY
authors.lastname: Kwak
authors.affiliation: j Department of Hematology , St Vincent's Hospital, The Catholic University of Korea , Suwon , Korea.
authors.forename: Jeong-A
authors.initials: JA
authors.lastname: Kim
authors.affiliation: k Department of Hematology , Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea.
authors.forename: Dae-Young
authors.initials: DY
authors.lastname: Kim
authors.affiliation: l Department of Hematology , School of Medicine, Ewha Womans University , Seoul , Korea.
authors.forename: Yeung-Chul
authors.initials: YC
authors.lastname: Mun
authors.affiliation: m Department of Internal Medicine , Inje University College of Medicine, Inje University Busan Paik Hospital , Busan , Korea.
authors.forename: Won Sik
authors.initials: WS
authors.lastname: Lee
authors.affiliation: n Department of Hematology-Oncology , National Health Insurance Service Ilsan Hospital , Ilsan , Korea.
authors.forename: Myung Hee
authors.initials: MH
authors.lastname: Chang
authors.affiliation: o Department of Hematology , Gachon University Gil Hospital , Incheon , Korea.
authors.forename: Jinny
authors.initials: J
authors.lastname: Park
authors.affiliation: p Department of Hematology-Oncology , Chungbuk National University Hospital , Cheongju , Korea.
authors.forename: Ji Hyun
authors.initials: JH
authors.lastname: Kwon
authors.affiliation: b Department of Hematology , Seoul St Mary's Hospital, The Catholic University of Korea , Seoul , Korea.
authors.forename: Dong-Wook
authors.initials: DW
authors.lastname: Kim
keywords: Chronic myeloid leukemia; imatinib cessation; quality-of-life